Digestive Diseases and Sciences

, Volume 55, Issue 12, pp 3508–3513 | Cite as

Abnormal Small-Intestinal Endocrine Cells in Patients with Irritable Bowel Syndrome

Original Article



General disturbances in gastrointestinal motility have been reported in patients with irritable bowel syndrome (IBS). The gastrointestinal tract hormones play an important role in regulating gastrointestinal motility.


To investigate a possible abnormality in the small intestinal endocrine cells of IBS patients.


Included in the study were 41 patients with irritable bowel syndrome according to Rome Criteria III and 42 healthy controls. Duodenal biopsies were obtained from both patients and controls during gastroscopy. The biopsies were immunostained by avidin–biotin-complex method for secretin, CCK, GIP, somatostatin, and serotonin cells. The cell densities were quantified by computerized image analysis.


The density of secretin- and CCK-immunoreactive cells in patients with IBS was significantly reduced. The reduction in secretin and CCK cells occurred only in IBS-diarrhea patients, but not in IBS-constipation subtype. Both GIP and somatostatin cell densities were reduced in the duodenum of IBS patients. There was no statistical difference between the subtypes of IBS patients, regarding secretin, CCK, GIP, or somatostatin cell densities. Serotonin cell density was not affected in patients with IBS.


The low densities of secretin and CCK cells in IBS-diarrhea patients may cause a functional pancreatic insufficiency as well as inadequate gall emptying, as these hormones stimulate pancreatic bicarbonate and enzyme secretion and CCK stimulates as well gall bladder contraction. Low densities of secretin, GIP, and somatostatin cells in IBS patients might result in a high secretion of gastric acid, as secretin, GIP, and somatostatin inhibit gastric acid secretion.


Computer image analysis Endocrine cells IBS Small intestine Immunohistochemistry 


  1. 1.
    Thompson WG. A world view of IBS. In: Camilleri M, Spiller R, eds. Irritable bowel syndrome: diagnosis and treatment. Philadelphia: Saunders; 2002:17–26.Google Scholar
  2. 2.
    Agreus L, Svarsudd K, Nygren O, et al. Irritable bowel syndrome and dyspepsia in general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–680.CrossRefPubMedGoogle Scholar
  3. 3.
    Thompson WG, Haeton KW. Functional bowel disorders in apparently healthy people. Gastorenterology. 1980;79:283–288.Google Scholar
  4. 4.
    Kennedy TM, Jones RH, Hungin AP, et al. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774.CrossRefPubMedGoogle Scholar
  5. 5.
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580.CrossRefPubMedGoogle Scholar
  6. 6.
    Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736–1741.CrossRefPubMedGoogle Scholar
  7. 7.
    Hugin AP, Whonwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Alment Pharmacol Ther. 2003;17:643–650.CrossRefGoogle Scholar
  8. 8.
    Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304:87–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Bordie AK. Functional disorders of the colon. J Indian Med Assoc. 1972;58:451–456.PubMedGoogle Scholar
  10. 10.
    O`Keefe EA, Talley NJ, Zinsmeister AR, et al. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Biol Sci Med Sci. 1995;50:M184–M189.Google Scholar
  11. 11.
    Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991;100:998–1005.PubMedGoogle Scholar
  12. 12.
    Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004;54:495–502.PubMedGoogle Scholar
  13. 13.
    Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet. 1983;1:632–634.CrossRefPubMedGoogle Scholar
  14. 14.
    Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 2009;11:265–269.CrossRefPubMedGoogle Scholar
  15. 15.
    Whitehead WE, Burnett CK, Cook EW III, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248–2253.CrossRefPubMedGoogle Scholar
  16. 16.
    Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health related quality of life. Gastroenterology. 2000;11:654–660.CrossRefGoogle Scholar
  17. 17.
    Huerta-Icelo I, Hinojosa C, Santa Maria A, et al. Diferencias en la calidad de vida (CV) entre pacientes con sindrome de Intestino irritable (SII) y la poblacon mexicana evaluadas mediante el SF-36. Rev Mex Gastroenterol. 2001;66(Suppl 2):145–146.Google Scholar
  18. 18.
    Schmulson M, Robles G, Kershenobich D, et al. Los pacientes con trastornos funcionales digestivos (TFD) tienen major compromiso de la calidad de vida (CV) evaluadas por el SF-36 comparados con pacientes con hepatitis C y pancreatitis cronica. Rev Mex Gastroenterol. 2000;65(Suppl-Resumenes):50–51.Google Scholar
  19. 19.
    Whorwell PJ, Clouter C, Smith CL. Oesophagus motility in the irritable bowel syndrome. BMJ. 1981;282:1101–1102.CrossRefPubMedGoogle Scholar
  20. 20.
    Caballero-Plasencia AM, Valenzula-Barranco M, Herrerias-Gutierrez JM, et al. Altered gastric emptying in patients with irritable bowel syndrome. Eur Nul Med. 1999;26:404–409.CrossRefGoogle Scholar
  21. 21.
    Evans PR, Bak YT, Shuter B, et al. Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Dig Dis Sci. 1997;42:2087–2093.CrossRefPubMedGoogle Scholar
  22. 22.
    van Wijk HJ, Smout AJ, Akkerman LM, et al. Gastric emptying and dyspeptic symptoms in irritable bowel syndrome. Scand J Gastroenterol. 1992;27:99–102.CrossRefPubMedGoogle Scholar
  23. 23.
    Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relation of disorders in the transit of single solid meal top symptom patterns. Gut. 1983;24:405–411.CrossRefPubMedGoogle Scholar
  24. 24.
    Kellow JE, Philips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92:1885–1893.PubMedGoogle Scholar
  25. 25.
    Kellow JE, Philips SF, Miller LJ, et al. Dysmotility of the small bowel in irritable bowel syndrome. Gut. 1988;29:1236–1243.CrossRefPubMedGoogle Scholar
  26. 26.
    El-Salhy M. Gut neuroendocrine system in diabetes gastroenteropathy: possible role in pathophysiology and clinical implications. In: Ford AM, ed. Focus on diabetes mellitus research. New York: Nova Science Publishers; 2006:79–102.Google Scholar
  27. 27.
    Lee KJ, Kim JH, Kwon HC, et al. The alteration of enterochromaffin cells, mast cells, and Lamnia propria T lymphocyte numbers in irritable bowel syndrome and its relation with psychological factors. J Gastroenterol Hepatol. 2008;23:1689–1694.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 2007;13:6041–6047.CrossRefPubMedGoogle Scholar
  29. 29.
    Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–811.CrossRefPubMedGoogle Scholar
  30. 30.
    Wheatcroft J, Wakelin D, Smith A, et al. Enterochromaffin cell hyperplasia and decreased serotonin transporter in mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil. 2005;17:863–870.CrossRefPubMedGoogle Scholar
  31. 31.
    Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651–1659.CrossRefPubMedGoogle Scholar
  32. 32.
    Park JH, Rhee P-L, Kim G, et al. Enteroendocrine cell counts correlated with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2006;18:539–546.CrossRefPubMedGoogle Scholar
  33. 33.
    Van Der Veek PP, Biemond I, Masclee AA. Proximal and distal gut hormone secretion in irritable bowel syndrome. Scand J Gastroenterol. 2006;41:170–177.CrossRefGoogle Scholar
  34. 34.
    El-Salhy M, Stenling R, Grimelius L. Peptidergic innervation and endocrine cells in the human liver. Scand J Gastroenterol. 1993;28:809–815.CrossRefPubMedGoogle Scholar
  35. 35.
    Sandström O, El-Salhy M. Aging and endocrine cells of human duodenum. Mech Ageing Develop. 1999;108:39–48.CrossRefGoogle Scholar
  36. 36.
    El-Salhy M, Norrgård Ö, Spinnell S. Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand J Gastroenterol. 1999;34:1007–1011.CrossRefPubMedGoogle Scholar
  37. 37.
    El-Salhy M, Lillebø E, Reinemo A, Salmelid L. Ghrelin in patients with irritable bowel syndrome. Internat J Mol Med. 2009;23:703–707.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Magdy El-Salhy
    • 1
    • 2
  • K. Vaali
    • 2
  • V. Dizdar
    • 2
  • T. Hausken
    • 2
  1. 1.Section for Gastroenterology, Department of MedicineStord Helse-Fonna HospitalStordNorway
  2. 2.Section for Gastroenterology, Institute of MedicineUniversity of BergenBergenNorway

Personalised recommendations